Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

MLA

Morabito, Nancy, et al. “Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, vol. 19, no. 11, Nov. 2004, pp. 1766–70. EBSCOhost, https://doi.org/10.1359/JBMR.040813.

APA

Morabito, N., Gaudio, A., Lasco, A., Catalano, A., Atteritano, M., Trifiletti, A., Anastasi, G., Melloni, D., & Frisina, N. (2004). Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, 19(11), 1766–1770. https://doi.org/10.1359/JBMR.040813

Chicago

Morabito, Nancy, Agostino Gaudio, Antonino Lasco, Antonino Catalano, Marco Atteritano, Aldo Trifiletti, Giuseppina Anastasi, Darwin Melloni, and Nicola Frisina. 2004. “Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research 19 (11): 1766–70. doi:10.1359/JBMR.040813.